Skip to content

The advantages and mechanism of the treatment of unstable angina pectoris from 'Yu-Du (silted toxin)' based therapy of TCM theory

The advantages and mechanism of the treatment of unstable angina pectoris from 'Yu-Du (silted toxin)' based therapy of TCM theory

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024691
Enrollment
Unknown
Registered
2019-07-22
Start date
2017-07-01
Completion date
Unknown
Last updated
2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

Sponsors

Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
47 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Meet the unstable angina and non ST segment elevation myocardial infarction diagnosis and treatment guidelines of the early hairstyle exertional angina, deteriorating exertional angina, spontaneous angina or mixed angina patients; The clinical risk stratification standard is low and middle critical. 2. angina severity classification for I, II, and III; 3. The TCM syndrome differentiation is the heat - toxic blood stasis type; 4. Aged between 18 and 75 years old; 5. Been sign informed consent.

Exclusion criteria

Exclusion criteria: 1. The patients with high risk or angina classification in the clinical risk stratification were classified as patients; 2. The combined hypertension was more than 180/100mmhg; 3. The electrocardiogram had st-segment elevation, serious arrhythmia, and moderate or above cardiac dysfunction (EF < 40%); 4. Severe shock, liver, kidney, lung, etc. 5. In the past 3 months, AMI history or percutaneous coronary angioplasty (PTCA), coronary artery bypass surgery (CABG), severe trauma, cerebrovascular accident; 6. Obvious infection, fever, severe anemia; 7. Women who are pregnant or lactating; 8. It is difficult to complete hospitalization continuous observer due to poor compliance.

Design outcomes

Primary

MeasureTime frame
High-sensitive C reactive protein;Interleukin 6;interleukin 10;Tumor necrosis factor;adiponectin;

Countries

China

Contacts

Public ContactWu Min

Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences

wumin19762000@126.com+86 13671206090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026